Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

C4591007 Clinical Trial Group; Simões, Eric A.F.; Klein, Nicola P.; Sabharwal, Charu; Gurtman, Alejandra; Kitchin, Nicholas; Ukkonen, Benita; Korbal, Piotr; Zou, Jing; Xie, Xuping; Sarwar, Uzma N.; Xu, Xia; Lockhart, Stephen; Cunliffe, Luke; Lu, Claire; Ma, Hua; Swanson, Kena A.; Koury, Kenneth; Shi, Pei Yong; Cooper, David; Türeci, Ozlem; Jansen, Kathrin U.; Şahin, Uğur; Gruber, William C. (2023-03)
 
Avaa tiedosto
Lataukset: 



C4591007 Clinical Trial Group
Simões, Eric A.F.
Klein, Nicola P.
Sabharwal, Charu
Gurtman, Alejandra
Kitchin, Nicholas
Ukkonen, Benita
Korbal, Piotr
Zou, Jing
Xie, Xuping
Sarwar, Uzma N.
Xu, Xia
Lockhart, Stephen
Cunliffe, Luke
Lu, Claire
Ma, Hua
Swanson, Kena A.
Koury, Kenneth
Shi, Pei Yong
Cooper, David
Türeci, Ozlem
Jansen, Kathrin U.
Şahin, Uğur
Gruber, William C.
03 / 2023


doi:10.1093/jpids/piad015
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202309088041

Kuvaus

Peer reviewed
Tiivistelmä
In this ongoing study, substantially increased ancestral SARSCoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable.
Kokoelmat